305
Participants
Start Date
April 9, 2020
Primary Completion Date
February 2, 2023
Study Completion Date
June 27, 2024
Atezolizumab
Atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
Placebo
Placebo matching to atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
Bevacizumab
Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
Paclitaxel
Paclitaxel will be administered by IV infusion at a dose of 175 mg/m2.
Pemetrexed
Pemetrexed will be administered by IV infusion at a dose of 500 mg/m2.
Carboplatin
Carboplatin will be administered by IV infusion to achieve an initial target AUC of 6 mg/mL/min.
Peking Union Medical College Hospital, Beijing
Beijing Cancer Hospital, Beijing
Beijing Chest Hospital; Oncology Department, Beijing
The 900th Hospital of PLA joint service support force, Fuzhou
Liaoning cancer Hospital & Institute, Shenyang
the First Hospital of Jilin University, Changchun
Jilin Cancer Hospital, Changchun
Harbin Medical University Cancer Hospital, Harbin
Fudan University Shanghai Cancer Center, Shanghai
Shanghai Pulmonary Hospital, Shanghai
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing
Nan Tong Tumor Hospital, Nantong
Shandong Cancer Hospital, Jinan
Sir Run Run Shaw Hospital, Hangzhou
Zhejiang Cancer Hospital, Zhejiang
The First Affiliated Hospital of Xiamen University, Xiamen
Union Hospital of Tongji Medical College, Dept. of Cancer Center; Cancer Center, Wuhan
Hubei Cancer Hospital, Wuhan
Henan Cancer Hospital, Zhengzhou
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou
Guangxi Cancer Hospital of Guangxi Medical University, Nanning
West China Hospital, Sichuan University, Chengdu
First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an
Hoffmann-La Roche
INDUSTRY